Pirarubicin-loaded CalliSpheres® drug-eluting beads for the treatment of patients with stage III–IV lung cancer
- 20 February 2021
- journal article
- research article
- Published by SAGE Publications in Acta Radiologica
- Vol. 63 (3), 311-318
- https://doi.org/10.1177/0284185121994298
Abstract
CalliSpheres® beads (CB) have been used recently for patients with hepatocellular carcinoma. However, the safety and effect of drug-eluting bead transarterial chemoembolization (DEB-TACE) in patients with stage III–IV lung cancer are still unknown. To evaluate the safety and efficacy of DEB-TACE with pirarubicin-loaded CB for the treatment of stage III–IV lung cancer. From July 2016 to April 2020, 29 patients with stage III–IV primary lung cancer underwent DEB-TACE with pirarubicin-loaded CB. The objective response rate (ORR) was the primary endpoint; the secondary endpoints were progression-free survival (PFS) and overall survival (OS). Twenty-nine patients received DEB-TACE with pirarubicin-loaded (median 60 mg) CB, with no severe adverse events or treatment-related deaths. After DEB-TACE, hemoptysis disappeared within 1–3 days in all patients, and the symptoms of cough or expectoration were significantly improved in 12 patients. ORR and disease control rate at one, three, and six months after DEB-TACE were 39.3% and 96.4%, 26.1% and 69.6%, and 29.4% and 58.8%, respectively. The median PFS was 6.3 months (range 1.1–30.1 months), and the three-, six-, and 12-month PFS rates were 70.2%, 50.1%, and 27.1%, respectively. The median OS was 10.2 months (range 1.1–44.6 months), and the three-, six, and 12-month OS rates were 87.9%, 68.6%, and 39.8%, respectively. DEB-TACE with pirarubicin-loaded CB is safe, feasible, and well-tolerated for patients with stage III–IV lung cancer, and symptom control was a potential benefit of treatment.Keywords
This publication has 20 references indexed in Scilit:
- CalliSpheres drug-eluting beads versus lipiodol transarterial chemoembolization in the treatment of hepatocellular carcinoma: a short-term efficacy and safety studyWorld Journal of Surgical Oncology, 2018
- Bronchial artery chemoembolization combined with radioactive iodine-125 seed implantation in the treatment of advanced nonsmall cell lung cancerJournal of Cancer Research and Therapeutics, 2017
- Comparison of pharmacokinetics and drug release in tissues after transarterial chemoembolization with doxorubicin using diverse lipiodol emulsions and CalliSpheres Beads in rabbit liversDrug Delivery, 2017
- Nine-year experience of doxorubicin-eluting beads chemoembolization for hepatocellular carcinomaHepatobiliary & Pancreatic Diseases International, 2016
- [Efficacy for artery chemoembolization combined with radiofrequency ablation in the treatment of advanced non-small cell lung cancer].Published by Ovid Technologies (Wolters Kluwer Health) ,2016
- Treatment of Liver Tumors with Lipiodol TACE: Technical Recommendations from Experts OpinionCardioVascular and Interventional Radiology, 2015
- Transcatheter Arterial Embolization With Spherical Embolic Agent for Pulmonary Metastases From Renal Cell CarcinomaCardioVascular and Interventional Radiology, 2013
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- [A prospective randomized trial comparing mitomycin C and vindesine and cisplatin versus pirarubicin and vindesine and cisplatin in the treatment of advanced non-small cell lung cancer].2003